Dravet Syndrome Market

Key Highlights

• As per DelveInsight, the Dravet Syndrome Market is expected to expand at a healthy growth rate during the forecast period (2024-2034), owing to the launch of new therapies in the market and the rise in the number of cases. 
• Several major pharma and biotech companies such as Biocodex, GW Pharmaceuticals, Zogenix, Ovid Therapeutics, PTC Therapeutics, Takeda, Epygenix Therapeutics, Stoke Therapeutics, Longboard Pharmaceuticals, Encoded Therapeutics, Eisai, Virpax Pharmaceuticals, among others, are actively working in the Dravet Syndrome Market.
• In January 2025, the FDA granted rare pediatric disease designation to relutrigine, a treatment for Dravet syndrome developed by Praxis Precision Medicines. The therapy aims to reduce seizures in children with epileptic disorders like Dravet.
• In December 4, 2024, Stoke Therapeutics, Inc. announced that the FDA granted Breakthrough Therapy Designation to zorevunersen for the treatment of Dravet syndrome with a confirmed mutation in the SCN1A gene, not associated with gain-of-function.

Download the Sample PDF to Get More Insight @ Dravet Syndrome Market

DelveInsight's "Dravet Syndrome Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Dravet Syndrome, historical and forecasted epidemiology as well as the Dravet Syndrome therapeutics market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Dravet Syndrome market report provides current treatment practices, emerging drugs, Dravet Syndrome market share of the individual therapies, current and forecasted Dravet Syndrome market Size from 2020 to 2034 segmented by seven major markets. The Report also covers current Dravet Syndrome treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Dravet Syndrome market. 

Dravet SyndromeTreatment Market

According to the Dravet Syndrome Foundation, Dravet Syndrome (DS) is classified as a rare and severe form of epilepsy, characterized by its lifelong impact on individuals. This debilitating condition typically manifests within the first year of life, presenting with a relentless pattern of frequent and often prolonged seizures. Dravet Syndrome significantly disrupts the lives of those affected, demanding specialized care and comprehensive research efforts to improve the management and outcomes of this rare epilepsy disorder.

According to National Organization for Rare Disorders (NORD), Dravet Syndrome (DS) is a severe form of epilepsy characterized by frequent, prolonged seizures often triggered by high body temperature (hyperthermia), developmental delay, speech impairment, ataxia, hypotonia, sleep disturbances, and other health problems.

Mutations of ion channels have a major role in the pathogenesis of epilepsy syndromes thus, it is also referred as “channelopathy”. Convulsive seizures triggered by a fever, typically around 5 to 8 months of age are the earliest symptoms of Dravet Syndrome.

Currently, there is a notable absence of organizational or authoritative consensus regarding the diagnostic criteria for Dravet Syndrome. This lack of standardized guidelines often leads to initial misdiagnosis, particularly in children, as conventional tests like MRI and EEG may appear normal in infants with Dravet syndrome. Consequently, a critical challenge lies in accurately identifying and classifying this condition. 

The primary objective of existing treatments is to substantially reduce the frequency of seizures while minimizing the potential toxicity associated with antiepileptic medications. The therapeutic approach encompasses a range of options, including medications such as Clobazam, Valproic acid, Stiripentol, Topiramate, and Levetiracetam, as well as interventions like Vagus nerve stimulation. As research continues to advance, it is essential to establish diagnostic criteria and optimize treatment strategies to improve the outcomes and quality of life for individuals living with Dravet Syndrome.

Dravet Syndrome Epidemiology 

The Dravet Syndrome epidemiology section provides insights about the historical and current Dravet Syndrome patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Dravet Syndrome market report also provides the diagnosed patient pool and their trends along with assumptions undertaken. 

The disease epidemiology covered in the report provides historical as well as forecasted Dravet Syndrome epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2020 to 2034.

Key Findings

• According to NORD (2018), Dravet Syndrome affects an estimated 1:15,700 individuals in the US, or 0.0064% of the population. Approximately 80-90% of those, or 1:20,900 individuals, have both an SCN1A mutation and a clinical diagnosis of DS. This represents an estimated 0.17% of all epilepsies
• According to Dravet Syndrome Foundation (2022), a recent US epidemiology study concluded that Dravet Syndrome is twice as common as previously recognized, affecting 1:15,700 infants, 80% of whom have an SCN1A mutation.
• As per the study by Gil-Nagel et al. (2020), the average incidence rate among pediatric and adult patients is 1.1 cases and 0.5 cases per million inhabitants, respectively in Spain.
• In the UK, the total number of treated Dravet Syndrome cases ave been estimated at around 1,000 cases in 2022.
• In the US, the total incident Dravet Syndrome cases have been estimated at around 21,760 cases in 2022.
• In France, the total diagnosed Dravet Syndrome cases have been estimated at around 1,050 cases in 2022.
• In Japan, the total incident Dravet Syndrome cases have been estimated around 2,800 cases in 2022.

Country Wise- Dravet Syndrome Epidemiology

The epidemiology segment also provides the Dravet Syndrome epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Discover key insights on Dravet Syndrome prevalence! Stay updated on prevalence, trends, and future projections for better awareness and care.

The Report Covers the Dravet Syndrome Epidemiology Segmented as 

• Total Incident Cases of Dravet Syndrome 
• Total Diagnosed Cases of Dravet Syndrome 
• Mutation-Specific Incident Cases of Dravet Syndrome 
• Age-specific Incident Cases of Dravet Syndrome 
• Gender-specific Incident Cases of Dravet Syndrome 
• Total Treated Cases of Dravet Syndrome 

Dravet Syndrome Recent Developments

• In September 2025, Encoded Therapeutics received FDA RMAT designation for ETX101, a gene therapy targeting SCN1A+ Dravet syndrome, following promising Phase 1/2 seizure data. ETX101 also holds Fast Track, Rare Pediatric, and Orphan Drug designations from the FDA.
• In December 2024, the FDA granted rare pediatric disease designation to relutrigine, a treatment for Dravet syndrome developed by Praxis Precision Medicines. The therapy aims to reduce seizures in children with epileptic disorders like Dravet.
• In December 2024, Stoke Therapeutics, Inc. announced that the FDA granted Breakthrough Therapy Designation to zorevunersen for the treatment of Dravet syndrome with a confirmed mutation in the SCN1A gene, not associated with gain-of-function.

Dravet Syndrome Drug Chapters

The drug chapter segment of the Dravet Syndrome report encloses the detailed analysis of Dravet Syndrome marketed drugs and late-stage (Phase-III and Phase-II) Dravet Syndrome pipeline drugs. It also helps to understand the Dravet Syndrome clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases. Dravet syndrome pipeline drugs analysis highlights emerging treatments, ongoing clinical trials, novel therapies, and market trends shaping the future of epilepsy care.

Discover the future of Dravet Syndrome treatments! Explore emerging therapies and key players in the Dravet Syndrome Pipeline Insight, 2025!  

Dravet Syndrome Marketed Drugs

The report provides the details of the marketed products/off-label treatments available for Dravet Syndrome treatment.

Dravet Syndrome Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Dravet Syndrome treatment. The Dravet syndrome mechanism involves mutations in the SCN1A gene, leading to dysfunctional sodium channels, causing severe epilepsy and neurodevelopmental impairments.

Dravet Syndrome Market Outlook

The Dravet Syndrome market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Dravet Syndrome market trends by analyzing the impact of current Dravet Syndrome therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Dravet Syndrome market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Dravet Syndrome market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Dravet Syndrome market in 7MM is expected to witness a major change in the study period 2020-2034.

Key Findings

This section includes a glimpse of the Dravet Syndrome market in 7MM.

The United States Market Outlook

This section provides the total Dravet Syndrome market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Dravet Syndrome market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Dravet Syndrome market size and market size by therapies in Japan is also mentioned.

Dravet Syndrome Drugs Uptake

This section focuses on the rate of uptake of the Dravet Syndrome drugs recently launched in the Dravet Syndrome market or expected to get launched in the market during the study period 2020-2034. The analysis covers Dravet Syndrome market uptake by drugs; patient uptake by therapies; and sales of each drug. Dravet syndrome clinical trial analysis examines emerging therapies, trial outcomes, patient responses, and future treatment advancements for this rare epilepsy disorder.

Dravet Syndrome Drugs Uptake helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs on the basis of Dravet Syndrome market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Dravet Syndrome Pipeline Development Activities

The Dravet Syndrome report provides insights into Dravet Syndrome clinical trials within Phase II, and Phase III stage. It also analyses Dravet Syndrome key players involved in developing targeted therapeutics.

Pipeline Development Activities

The Dravet Syndrome report covers the detailed information of collaborations, acquisition, and merger, licensing, patent details, and other information for Dravet Syndrome emerging therapies.

Dravet Syndrome Market Dynamics and Key Companies in the Domain

The Dravet Syndrome market is poised for growth in the upcoming years, driven by several key factors. Firstly, the emergence of novel drugs and therapeutic approaches holds significant promise for improving the lives of individuals affected by Dravet Syndrome. Additionally, the global increase in healthcare spending underlines the growing commitment to addressing this rare condition. The high incidence rate of Dravet Syndrome further accentuates the market's potential, as it emphasizes the urgency of developing effective treatments. Moreover, active participation by key players in the therapeutics market, including pharmaceutical companies and research institutions, is instrumental in driving advancements and expanding the available treatment options. This multifaceted landscape offers hope for better management and enhanced quality of life for Dravet Syndrome patients in the upcoming years. 

Some of the key companies such as Biocodex, GW Pharmaceuticals, Zogenix, Ovid Therapeutics, PTC Therapeutics, Takeda, Epygenix Therapeutics, Stoke Therapeutics, Longboard Pharmaceuticals, Encoded Therapeutics, Eisai, Virpax Pharmaceuticals, and others are actively working in the Dravet Syndrome therapeutics market. 

Reimbursement Scenario in Dravet Syndrome

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current Dravet Syndrome market trends, we take KOLs and SMEs ' opinion working in the Dravet Syndrome domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Dravet Syndrome market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Dravet Syndrome Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Dravet Syndrome Market Report

• The report covers the descriptive overview of Dravet Syndrome, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Dravet Syndrome epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Dravet Syndrome is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of the Dravet Syndrome market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Dravet Syndrome market

Dravet Syndrome Market Report Highlights

• In the coming years, the Dravet Syndrome market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Dravet Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition      
• Major players are involved in developing therapies for Dravet Syndrome. The launch of emerging therapies will significantly impact the Dravet Syndrome market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Dravet Syndrome
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Dravet Syndrome Report Insights

• Dravet Syndrome Patient Population
• Dravet Syndrome Therapeutic Approaches
• Dravet Syndrome Pipeline Analysis
• Dravet Syndrome Market Size and Trends
• Dravet Syndrome Market Opportunities
• Impact of upcoming Dravet Syndrome Therapies

Dravet Syndrome Report Key Strengths

• 10 Years Forecast
• 7MM Coverage
• Dravet Syndrome Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Dravet Syndrome Drugs Uptake

Dravet Syndrome Report Assessment

• Dravet Syndrome Current Treatment Practices
• Dravet Syndrome Unmet Needs
• Dravet Syndrome Pipeline Product Profiles
• Dravet Syndrome Market Attractiveness
• Dravet Syndrome Market Drivers
• Dravet Syndrome Market Barriers

Key Questions Answered In The Dravet Syndrome Market Report:

Dravet Syndrome Market Insights

• What was the Dravet Syndrome drug class share (%) distribution in 2020 and how it would look like in 2034?
• What would be the Dravet Syndrome total market size as well as market size by therapies across the 7MM during the forecast period (2020-2034)?
• What are the key findings pertaining to the market across 7MM and which country will have the largest Dravet Syndrome market size during the forecast period (2020-2034)?
• At what CAGR, the Dravet Syndrome market is expected to grow by 7MM during the forecast period (2020-2034)?
• What would be the Dravet Syndrome market outlook across the 7MM during the forecast period (2020-2034)?
• What would be the Dravet Syndrome market growth till 2034, and what will be the resultant market Size in the year 2034?
• How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?

Dravet Syndrome Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of the Dravet Syndrome?
• What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What is the historical Dravet Syndrome patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Dravet Syndrome in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• Where will be the growth opportunities in the 7MM with respect to the patient population pertaining to Dravet Syndrome?
• Out of all 7MM countries, which country would have the highest prevalent population of Dravet Syndrome during the forecast period (2020-2034)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2020-2034)?

Current Dravet Syndrome Treatment Scenario, Marketed Drugs and Emerging Therapies:

• What are the current options for the Dravet Syndrome treatment in addition to the approved therapies?
• What are the current treatment guidelines for the treatment of Dravet Syndrome in the USA, Europe, and Japan?
• What are the Dravet Syndrome marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
• How many companies are developing therapies for the treatment of Dravet Syndrome?
• How many therapies are in-development by each company for Dravet Syndrome treatment?
• How many are emerging therapies in mid-stage, and late stage of development for Dravet Syndrome treatment?
• What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Dravet Syndrome therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies being developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Dravet Syndrome and their status?
• What are the current challenges faced in drug development?
• What are the key designations that have been granted for the emerging therapies for Dravet Syndrome?
• What are the global historical and forecasted market of Dravet Syndrome?

Reasons to buy Dravet Syndrome Market Forecast Report

• The report will help in developing business strategies by understanding trends shaping and driving the Dravet Syndrome market
• To understand the future market competition in the Dravet Syndrome market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Dravet Syndrome in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for Dravet Syndrome market
• To understand the future market competition in the Dravet Syndrome market